Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 7Genitourinary 6Gastrointestinal 5Thoracic 3Sarcoma 3Other solid neoplasm 3Lymphoid 3Tumor-Agnostic 1Plasma cell 1Other hematologic neoplasm 1NET 1Head & Neck 1Gynecologic 1Endocrine 1

Conditions

Prostatic Neoplasms 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Neoplasms 1Disease Progression 1Breast Neoplasms 1

Interventions

Paclitaxel 581Carboplatin 527Cisplatin 355Bevacizumab 256pembrolizumab 226Gemcitabine 157liposomal doxorubicin 132Topotecan 131olaparib 129Cyclophosphamide 126Radiotherapy 118Taxes 114Docetaxel 95Brachytherapy 94Drug Therapy 90niraparib 88Doxorubicin 86Surveys and Questionnaires 85Magnetic Resonance Spectroscopy 80Blood Specimen Collection 73Nivolumab 71Specimen Handling 70Hyperthermic Intraperitoneal Chemotherapy 64Biopsy 63fludarabine 56Filgrastim 53Letrozole 50Oxaliplatin 49durvalumab 47Immunoglobulin G 47

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Clinical Trials, Phase II as Topic × Gynecologic × Clear all
NCT04503265 2025-05-01

A Trial of AMXI-5001 for Treatment in Patients With Advanced Malignancies

AtlasMedx, Incorporated

Phase 1/2 Recruiting
122 enrolled
BreastGastrointestinalGenitourinaryGynecologic

Breast Neoplasms, Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Disease Progression

Data powered by HemOnc (CC BY 4.0) Colophon âš¡